
The Weighty Shift: Obesity Drug Giants Face New Challenges Under Kennedy’s Watch
Robert F. Kennedy Jr.’s appointment as head of the Department of Health brings scrutiny to the weight loss drug industry. Eli Lilly and Novo Nordisk face uncertainty as Kennedy criticizes the widespread use of obesity medications. There is potential for a transformative